Business Context and Reporting Period
This Form 8-K filing by Ocular Therapeutix, Inc. (Delaware) is dated July 30, 2014. The report details corporate governance changes and charter amendments executed in connection with the closing of the Company's Initial Public Offering (IPO).
Key Financial Metrics
The filing text does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. This report focuses exclusively on corporate structural changes.
Material Changes
- Board Composition: Mr. Alan Crane resigned from the Board of Directors effective July 30, 2014, immediately prior to the IPO closing. His resignation was not related to any disagreements regarding operations, policies, or practices. Mr. Bruce Peacock was appointed and elected to the Board in July 2014 to precede Mr. Crane's departure.
- Charter Amendments: The Company filed a Restated Certificate of Incorporation with the State of Delaware. Key provisions include:
- Authorization of 100,000,000 shares of common stock.
- Elimination of all references to previously existing preferred stock series.
- Authorization of 5,000,000 shares of undesignated preferred stock.
- Establishment of a classified board with three classes of directors serving staggered three-year terms.
- Restrictions on director removal (only for cause with a 75% stockholder vote).
- Elimination of stockholder ability to take action by written consent or call special meetings.
- Bylaw Amendments: Amended and Restated By-laws became effective upon the IPO closing, aligning with the Restated Certificate. These changes formalize procedures for stockholder proposals and director nominations while eliminating written consent actions.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management outlook, or specific risk factors beyond the standard disclosure that the description of the Restated Certificate and By-laws is qualified by reference to the full text of the documents attached as exhibits.
Investor Verification Checklist
- Verify the full text of the Restated Certificate of Incorporation (Exhibit 3.1) for specific anti-takeover provisions and director removal thresholds.
- Confirm the details of the Amended and Restated By-laws (Exhibit 3.2) regarding stockholder proposal and nomination procedures.
- Review the IPO prospectus referenced in the filing for the complete context of Mr. Crane's resignation and Mr. Peacock's appointment.
- Check subsequent filings for the actual IPO pricing and capital raised, as this 8-K does not disclose those figures.